Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Guidance and quality standards
Awaiting development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Filter by title or keyword
Filter
Area of interest
Area of interest
COVID-19 (9)
Type
Type
Guidance (309)
Quality standard (30)
Guidance programme
Guidance programme
Diagnostics guidance (2)
Health technology evaluations (1)
Highly specialised technologies guidance (1)
Interventional procedures guidance (15)
Medical technologies guidance (7)
Technology appraisal guidance (283)
Apply filters
Showing 1 to 25 of 339
Guidance and quality standards awaiting development
Title
Type
10395 - Aprocitentan for treating resistant hypertension TS ID 10395
Technology appraisal guidance
Abatacept for treating active idiopathic inflammatory myopathies TS ID 10095
Technology appraisal guidance
Abdominal aortic aneurysm
Quality standard
Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]
Technology appraisal guidance
Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]
Technology appraisal guidance
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]
Technology appraisal guidance
Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]
Technology appraisal guidance
Acalabrutinib with venetoclax for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma TS ID 11823
Technology appraisal guidance
Acne
Quality standard
Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy TS ID 11904
Technology appraisal guidance
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer [ID6339]
Technology appraisal guidance
Adalimumab for treating early Dupuytren's contracture TS ID 11870
Technology appraisal guidance
Adrenal dysfunction
Quality standard
Adults with lifelong or very severe hearing or visual impairment: health, well-being and social care
Quality standard
Advocacy services for adults with health and social care needs
Quality standard
Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064]
Technology appraisal guidance
AI-supported colorectal polyp detection
Health technology evaluation
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over TS ID 10680
Technology appraisal guidance
Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments TS ID 11830
Technology appraisal guidance
Ambulatory pulmonary artery pressure monitoring devices
Diagnostics guidance
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]
Technology appraisal guidance
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]
Technology appraisal guidance
Apadamtase alfa for preventing and treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]
Technology appraisal guidance
Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer TS ID 11967
Technology appraisal guidance
Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia
Medical technologies guidance
Current page
1
2
3
…
14
Page
1
of
14
Next page
Results per page
10
25
50
All
Back to top